NOW RECRUITING: Patients with Pulmonary Arterial Hypertension (PAH) for IMPAHCT,
a Phase 2b/3 study evaluating AV-101. Learn more about the study.

Josh Resnick, MD

Josh is a Managing Director at RA Capital Management. He has more than 15 years of experience in investing, company formation, and company leadership across all stages of drug development, from discovery through commercialization.